Stock Screener App

무료 -

2.08

4.00% +0.08

SILO Pharma Inc (SILO)

개요 뉴스 가격 이력 Financials 토론 예측 주식 분할

SILO Pharma Inc 주식(SILO)의 최신 뉴스

Market Update: SILO Pharma Inc (SILO) Sees Negative Movement, Closing at 1.92 – DWinneX - The Dwinnex

Short Interest in Silo Pharma, Inc. (NASDAQ:SILO) Decreases By 26.4% - Defense World

Investing in SILO Pharma Inc [SILO]: What You Must Know – Knox Daily - Knox Daily

SILO’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

The InvestChronicle

Silo Pharma (NASDAQ:SILO) Trading Up 7.4% - Defense World

Silo Pharma (NASDAQ:SILO) Trading Up 7.4% - Defense World

Silo Pharma reports progress in depression treatment study By Investing.com - Investing.com

Silo Pharma reports progress in depression treatment study - Investing.com India

Investing.com India

Revolutionizing Mental Healthcare With The Rise Of Ketamine And Psychedelic Therapies - ATAI Life Science - Benzinga

Revolutionizing Mental Healthcare With The Rise Of Ketamine And Psychedelic Therapies - ATAI Life Science - Benzinga

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention - GlobeNewswire

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention - Yahoo Finance

Silo Pharma to discuss ketamine treatments at FDA event - Investing.com Canada

Investing.com Canada

Silo Pharma to discuss ketamine treatments at FDA event - Investing.com

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine - GlobeNewswire

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine - WDRB

Silo Pharma to discuss ketamine treatments at FDA event - Investing.com

Head to Head Survey: Silo Pharma (NASDAQ:SILO) vs. Amer Sports (NYSE:AS) - Defense World

Analyzing Dominari (NASDAQ:DOMH) and Siebert Financial (NASDAQ:SIEB) - Defense World

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

GlobeNewswire Inc.

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment - Yahoo Finance

Silo Pharma Advances Alzheimer's Disease Treatment with SPC-14 - The Dales Report

The Dales Report

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic

GlobeNewswire Inc.

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic - Barron's

Citizens And 2 Other Stocks Under $3 Insiders Are Buying

Citizens And 2 Other Stocks Under $3 Insiders Are Buying - Citizens (NYSE:CIA), SILO Pharma (NASDAQ:SILO) - Benzinga

Silo Pharma CEO buys shares worth $1,988 By Investing.com - Investing.com Canada

Investing.com Canada

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying - Alzamend Neuro (NASDAQ:ALZN), Anitra (AMEX: - Benzinga

Silo Pharma Full Year 2023 Earnings: EPS Misses Expectations - Simply Wall St

Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic

GlobeNewswire Inc.

Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety ... - GlobeNewswire

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

GlobeNewswire Inc.

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain - Yahoo Finance

Global Psychedelic Drugs Market Size To Worth USD 8.7 Billion By 2033 | CAGR of 11.61% - GlobeNewswire

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

GlobeNewswire Inc.

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD - Yahoo Finance

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

GlobeNewswire Inc.

Silo Pharma's SP-26 Ketamine Implant Demonstrates - GlobeNewswire

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

GlobeNewswire Inc.

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology - Yahoo Finance

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

GlobeNewswire Inc.

Silo Pharma Announces Positive Results in Alzheimer's - GlobeNewswire

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

GlobeNewswire Inc.

SILO Stock Quote Price and Forecast - CNN

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD - GlobeNewswire

Silo Pharma Proceeds with Ketamine Implant for Chronic Pain - Green Market Report

Green Market Report

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

GlobeNewswire Inc.

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia - Yahoo Finance

Autoimmune Diseases Diagnostics Global Market to Surpass 6 Billion Mark by 2028 | DelveInsight - GlobeNewswire

$75.07

0.79%

$148.85

3.50%

$28.20

0.75%

$148.43

1.07%

$371.02

2.45%

$100.60

1.87%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기